Sfoglia per AUTORE
MORABITO F
Collezione AOU San Luigi di Orbassano

  

Items : 5

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. in Journal of hematology & oncology / J Hematol Oncol. 2019 Jan 9;12(1):4. doi: 10.1186/s13045-018-0691-4.

2019
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AO Cuneo
AOU Città della Salute di Torino
AOU Novara

Ria R; Vacca A; Dammacco F; Boccadoro M; Petrucci MT; Musto P; Montefusco V; Rizzo M; Gottardi D; Falcone AP; Grasso M; Leonardi G; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Patriarca F; Martino E; Larocca A; Offidani M; De Paoli L; Bringhen S; Palumbo A; Omedè P; Terragna C; Giuliani N; Morabito F; Saltarella I; et alii...

En-bloc laparoscopic nephroureterectomy without bladder opening in Journal of Endourology

2018
ASL Asti
AO Cuneo
AOU San Luigi di Orbassano

Negro C; Berta G; Morabito F; Zarrelli G; Dalmasso E; Maugeri O; Bernardi D; Chiapello G; Dadone C; Galletto E; Oppezzi F; Mediago M; Venzano F; Arena G; Porpiglia F; Fiori C; Amparore D; Giordano A; Manit A; Kadner G; Valerio M; Barber N; Lumen N; Ho B; Schulman C;

A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. in Leukemia / Leukemia. 2016 Jun;30(6):1320-6. doi: 10.1038/leu.2016.36. Epub 2016 Feb 22.

2016
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AOU Novara

Conticello C; Musolino C; De Paoli L; Nozzoli C; Aghemo E; Guglielmelli T; Genuardi M; Derudas D; Ponticelli E; Carella AM; Vincelli ID; Spada S; De Rosa L; Omedé P; Passera R; Montefusco V; Liberati AM; Morabito F; Benevolo G; Villani O; Falcone AP; Caravita T; Oliva S; Petrucci MT; Bringhen S; Larocca A; Offidani M; Boccadoro M; Sonneveld P; et alii...

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21.

2014
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AO Cuneo
AOU Città della Salute di Torino

Montefusco V; Zambello R; Gottardi D; Franceschini L; Grasso M; Vincelli ID; Benevolo G; Levi A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Palumbo A; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; et alii...

VMPT (bortezomib, melphalan, prednisone and thalidomide) followed by maintenance with bortezomib-thalidomide (VT) is active and well tolerated in newly diagnosed patients with multiple myeloma (MM) with moderate renal impairment (RI) ineligible for autologous stem cell transplantation: Results from a cohort analysis of a phase III randomized controlled trial in Haematologica

2011
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Morabito F; Gentile M; Mazzone C; Rossi D; Ria R; Offidani M; Patriarca F; Nozzoli C; Petrucci M; Benevolo G; Vincelli I; Guglielmelli T; Grasso M; Marasca R; Baldini L; Musto P; Liberati A; Cascavilla N; Cangialosi C; Majolino I; Musolino C; Zambello R; Di Raimondo F; Cavo M; Boccadoro M; Palumbo A;